Infinity Screening System Platform

A high-throughput microfluidic platform

The Infinity Screening System is a flexible, scalable, high-throughput microfluidic platform.

NemaLife created a future-proof life sciences platform by combining the top-notch technologies of our age, harnessing microfluidics, lab automation, machine learning aided image analysis, and data intelligence.

C. elegans is an established model organism for biological research, disease modeling, and drug discovery. NemaLife knows how laborious it can be to conduct whole-life assays and screening with C. elegans. Relying on our in-house microfluidics fabrication plant with funding from NIH, NSF, and NASA, we developed our patented core technology that offers unique benefits compared to agar, microplate, and even other microfluidics-based technologies.


Artificial biological selection (in animals)

Gregory Benford

Genescient is the first biomedical company founded to exploit artificial selection of animal models for longevity. Their extremely long-lived animal models (Drosophila melanogaster) have been developed over 700 generations, creating an ideal system for the study of aging and age-related disease because Drosophila metabolic genetic pathways are highly conserved in humans. To date they have discovered over 100 genomic targets, all related to the primary diseases of aging.

The speaker: Gregory Benford is the founder of Genescient in Fountain Valley, California, a biomedical company that’s mission is to extend healthy human lifespan by using advanced genomics to develop therapeutic substances that attack the diseases of aging. He is also Professor Emeritus of Physics at the University of California, Irvine. Professor Benford earned his PhD from the University of California, San Diego.